Maxime Barat1, Thi Thuy Linh Nguyen2, Clémence Hollande3, Jean-Baptiste Coty4, Christine Hoeffel5, Benoit Terris6, Anthony Dohan4, Vincent Mallet3, Stanislas Pol3, Philippe Soyer4. 1. Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France; Université de Paris, 75006, Paris, France. Electronic address: maxime.barat@aphp.fr. 2. Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France; Department of Radiology, Hue University of Medicine and Pharmacy, Hue University, Hue City, 530000, Viet Nam. 3. Université de Paris, 75006, Paris, France; Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France. 4. Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France; Université de Paris, 75006, Paris, France. 5. Department of Radiology, Hôpital Robert Debré, CRESTIC, URCA, 51000, Reims, France. 6. Université de Paris, 75006, Paris, France; Department of Pathology, Hôpital Cochin, AP-HP, 75014, Paris, France.
Abstract
PURPOSE: LI-RADS v2018 diagnostic system is used to diagnose hepatocellular carcinoma (HCC) in at risk patients. However, its applicability to HCC in non-alcoholic steatohepatitis (NASH) has not been specifically studied. The purpose of this study was to assess the applicability of LI-RADS v2018 diagnostic system for HCC in patients with NASH. MATERIALS AND METHODS: The MRI examinations of 41 patients with HCC and NASH (NASH group) were reviewed and compared to those obtained in 41 patients with HCC and virus-induced chronic liver disease (Virus group). MRI examinations of the two groups were compared for imaging presentation, LI-RADS major criteria and LI-RADS categorization. Qualitative variables were compared using Fisher exact test and quantitative variables using Mann-Whitney U test Interreader agreement was assessed using kappa statistic. RESULTS: No significant differences in qualitative and quantitative variables were observed between the two groups. Most common findings in the two groups were hyperenhancement during the arterial phase and visibility on T2-weighted images (93 % vs. 98 %, P = 0.616 and 85 % vs. 88 %, P = 1.000 for NASH group and Virus group, respectively). No differences in prevalence between the two groups were found for any major LI-RADS v2018 criterion. Interreader agreement for LI-RADS categorization was strong for the NASH group (kappa = 0.802) and moderate for the virus group (kappa = 0.720). No differences were found between the two groups for LI-RADS categories (P = 0.303). CONCLUSIONS: The LI-RADS v2018 diagnostic algorithm can be applied in patients with NASH.
PURPOSE:LI-RADS v2018 diagnostic system is used to diagnose hepatocellular carcinoma (HCC) in at risk patients. However, its applicability to HCC in non-alcoholic steatohepatitis (NASH) has not been specifically studied. The purpose of this study was to assess the applicability of LI-RADS v2018 diagnostic system for HCC in patients with NASH. MATERIALS AND METHODS: The MRI examinations of 41 patients with HCC and NASH (NASH group) were reviewed and compared to those obtained in 41 patients with HCC and virus-induced chronic liver disease (Virus group). MRI examinations of the two groups were compared for imaging presentation, LI-RADS major criteria and LI-RADS categorization. Qualitative variables were compared using Fisher exact test and quantitative variables using Mann-Whitney U test Interreader agreement was assessed using kappa statistic. RESULTS: No significant differences in qualitative and quantitative variables were observed between the two groups. Most common findings in the two groups were hyperenhancement during the arterial phase and visibility on T2-weighted images (93 % vs. 98 %, P = 0.616 and 85 % vs. 88 %, P = 1.000 for NASH group and Virus group, respectively). No differences in prevalence between the two groups were found for any major LI-RADS v2018 criterion. Interreader agreement for LI-RADS categorization was strong for the NASH group (kappa = 0.802) and moderate for the virus group (kappa = 0.720). No differences were found between the two groups for LI-RADS categories (P = 0.303). CONCLUSIONS: The LI-RADS v2018 diagnostic algorithm can be applied in patients with NASH.
Authors: Carlos Moctezuma-Velázquez; Sara Lewis; Karen Lee; Salvatore Amodeo; Josep M Llovet; Myron Schwartz; Juan G Abraldes; Augusto Villanueva Journal: JHEP Rep Date: 2021-09-16